Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 12/20 | 0.86 |
| ▸ | NMBR | P28336 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | BMP1 | P13497 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | ECE1 | P42892 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14070447 | 1.00 | TGM2 (0.86) | TGM2NMBRMAPTGAAHTT | |
| SCHEMBL4931009 | 1.00 | TGM2 (0.86) | TGM2NMBRMAPTGAAHTT | |
| SCHEMBL4299691 | 0.93 | TGM2 (1.00) | TGM2NMBRMAPTGAAHTT | |
| SCHEMBL1092215 | 0.92 | TGM2 (0.83) | TGM2NMBRMAPTGAAHTT | |
| SCHEMBL5143184 | 0.92 | TGM2 (0.83) | TGM2NMBRMAPTGAAHTT | |
| SCHEMBL1092213 | 0.92 | TGM2 (0.83) | TGM2NMBRMAPTGAAHTT | |
| SCHEMBL4935366 | 0.92 | TGM2 (0.73) | TGM2NMBRMAPTGAAHTT | |
| SCHEMBL9825335 | 0.91 | TGM2 (0.81) | TGM2NMBRMAPTGAAHTT | |
| SCHEMBL9826039 | 0.90 | TGM2 (0.71) | TGM2NMBRMAPTGAAHTT | |
| SCHEMBL4298214 | 0.90 | TGM2 (1.00) | TGM2NMBRMAPTGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080233102-A1 | Drug Therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-09-25 | — | — | US | claimed |
| JP-2007511607-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1706129-A1 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2006-10-04 | — | — | EP | claimed |
| WO-2005049064-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-06-02 | — | — | WO | claimed |
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | claimed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | claimed |
| US-20080299170-A1 | Medical Devices and Coatings Therefor | ASTON UNIVERSITY (GB) | 2008-12-04 | — | — | US | disclosed |
| US-20080233102-A1 | Drug Therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-09-25 | — | — | US | disclosed |
| EP-1907027-A2 | MEDICAL DEVICES AND COATINGS THEREFOR | Aston University (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007010201-A2 | MEDICAL DEVICES AND COATINGS THEREFOR | ASTON UNIVERSITY (GB) | 2007-01-25 | — | — | WO | disclosed |
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | disclosed |
| US-4929630-A | SKIN DISORDERS, ACNE, 4,5-DIHYDROISOOXAZOLE PEPTIDES | SYNTEX (U.S.A.) INC. (US) | 1990-05-29 | — | — | US | disclosed |
| US-4912120-A | Containing amine and amide substitution | SYNTEX (U.S.A.) INC. (US) | 1990-03-27 | — | — | US | disclosed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080233102-A1 | Drug Therapy for Celiac Sprue | SI, DNPEP, SPINT2 | TGM2 13/4885NMBR 3164/4885MAPT 1393/4885 |
| US-20080299170-A1 | Medical Devices and Coatings Therefor | F8, HABP2, TFPI | TGM2 16/4885NMBR 3605/4885MAPT 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.